Graticule Asia Macro Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Graticule Asia Macro Advisors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-109,500	Closed	-$7.4M	–	277
2018 Q2	$7.4M	Buy	+109,500	New	+$6.13M	0.47%	44
2017 Q3	–	Sell	-11,300	Closed	-$594K	–	135
2017 Q2	$594K	Buy	11,300 +2,480	+28%	+$115K	0.03%	105
2017 Q1	$400K	Sell	8,820 -18,580	-68%	-$829K	0.02%	116
2016 Q4	$1.04M	Buy	27,400 +11,400	+71%	+$431K	0.13%	83
2016 Q3	$604K	Buy	+16,000	New	+$353K	0.04%	92

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Graticule Asia Macro Advisors's AERI Position: Q3 2018 in Review

Graticule Asia Macro Advisors sold out of Aerie Pharmaceuticals (AERI) in Q3 2018, closing a stake of 109,500 shares — an estimated $7.4M sold.

Graticule Asia Macro Advisors first reported a position in AERI in Q3 2016 and held it in 5 quarters. The position peaked at $7.4M in Q2 2018. 176 funds tracked by Wall St. Rank hold AERI as of Q3 2018.

Graticule Asia Macro Advisors reported no remaining Aerie Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Graticule Asia Macro Advisors sold 109,500 Aerie Pharmaceuticals shares in Q3 2018, an estimated $7.4M.
Graticule Asia Macro Advisors first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 5 quarters.
Graticule Asia Macro Advisors's Aerie Pharmaceuticals position peaked at $7.4M in Q2 2018.
176 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2018.

Based on Graticule Asia Macro Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.